Company news
Starpharma Holdings Limited news in 2018
Starpharma Holdings Limited's news releases, calls and decks from 2018, newest first.
US FDA requests further data for VivaGel BV approval
December 27, 2018
US VivaGel BV licensed for A$142M milestones plus royalties
December 19, 2018
DEP products outperform in human pancreatic cancer model
November 16, 2018
Starpharma Investor Presentation for Citi Conference
October 16, 2018
DEP irinotecan outperforms in pancreatic cancer model
September 5, 2018
AstraZeneca DEP Bcl2/xL inhibitors show compelling efficacy
August 31, 2018
Annual report and full year financial results
August 21, 2018
VivaGel BV NDA advances to next stage of FDA review
July 9, 2018
Starpharma licenses VivaGel BV to Mundipharma for Europe
June 26, 2018
Mundipharma licenses Starpharmas VivaGel BV
May 3, 2018
Appendix 4C - Quarterly Cashflow Report
April 30, 2018
Starpharma completes US New Drug Application for VivaGel BV
April 29, 2018
Starpharma receives $3.7M R&D tax incentive refund
February 21, 2018
Starpharma to commence DEP cabazitaxel phase 1/2 trial
January 31, 2018
Decks in 2018
- Shareholder Meeting (November 2018)
Shareholder meeting · 40 slides · Nov 29, 2018
- Citi's 10th Annual Australian and New Zealand Investment Conference 2018
Conference · 35 slides · Oct 17, 2018